poisar

Stocks · News reference

AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties

Benzinga Newsdesk

The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

    The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

    JNJMLTXABBVAMGNTAK
  3. Sara Appino

    AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

    ABBVBMYCELGRMCKCAH